STOCK TITAN

PharmaCyte Biotech completes 1-for-19 reverse split

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Very High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

PharmaCyte Biotech, Inc. (PMCB) effected a 1-for-19 reverse stock split at 4:01 p.m. Eastern Time on November 12, 2026. Its common stock began trading on a split-adjusted basis at the open on November 13 on The Nasdaq Capital Market. The company said the split was intended to increase the per-share trading price to help it regain compliance with Nasdaq’s minimum bid price requirement.

The company said the split would reduce outstanding common shares from approximately 10,755,649 as of November 11, 2026, to approximately 566,087, while authorized shares remained unchanged. Proportional adjustments were made to outstanding options, warrants and convertible securities, and to shares under equity incentive plans. Holders entitled to fractional shares receive cash in lieu of those shares.

Item 3.03 Material Modification to Rights of Security Holders Securities
A change was made that materially affects the rights of existing shareholders (e.g., dividend rights, voting rights).
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Governance
The company amended its charter documents, bylaws, or changed its fiscal year.
Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Reverse stock split ratio 1-for-19 Effective November 12, 2026
Common shares outstanding before split Approximately 10,755,649 shares As of November 11, 2026
Common shares outstanding after split Approximately 566,087 shares Company-stated post-split amount
reverse stock split technical
"effect a reverse stock split of the Company’s common stock"
A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.
split-adjusted basis technical
"began trading on a split-adjusted basis"
An adjustment to historical share prices and share counts that reflects past stock splits or reverse splits so that old data lines up with the current number of shares. Think of it like resizing an old photograph so it matches a new frame: it keeps price charts, returns and per‑share metrics comparable over time, which matters to investors who need accurate performance, valuation and trend analysis.
fractional share technical
"entitled to a fractional share of Common Stock"
A fractional share is a portion of a single stock that is worth less than one full share, like owning a slice of a pizza instead of the whole pie. It lets investors buy and hold part of expensive stocks or spread small amounts of money across many companies, which helps with diversification and regular investing; dividends and price changes affect fractional shares proportionally, though some rights and trading rules can vary by provider.
minimum bid price requirement regulatory
"regain compliance with the minimum bid price requirement"
A minimum bid price requirement is a rule that a stock must trade above a set price for a specified period to stay listed on an exchange. It matters to investors because falling below that threshold can trigger warnings or removal from the exchange, which can cut liquidity, reduce visibility, and often lead to sharper declines in share value—think of it like a venue’s minimum dress code that, if not met, can bar a performer from the stage.
Split Ratio 1-for-19 reverse split
Effective Date November 12, 2026
Shares Before Split 10,755,649
Shares After Split 566,087
Share Count As Of November 11, 2026

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is PMCB’s reverse stock split ratio and when did it take effect?

PMCB effected a 1-for-19 reverse stock split at 4:01 p.m. Eastern Time on November 12, 2026. The common stock began trading on a split-adjusted basis at the open on November 13, 2026, on The Nasdaq Capital Market.

How many PMCB shares were outstanding after the reverse split?

The company said the split would reduce outstanding common shares from approximately 10,755,649 as of November 11, 2026, to approximately 566,087. The total authorized number of shares was not reduced.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false --04-30 0001157075 0001157075 2026-11-10 2026-11-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 8-K

 

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 10, 2026

 

PHARMACYTE BIOTECH, INC.

(Exact Name of Registrant as Specified in its Charter)

 

Nevada 001-40699 62-1772151
(State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.)

 

3960 Howard Hughes Parkway, Suite 500
Las Vegas
, Nevada
89169
(Address of Principal Executive Offices) (Zip Code)

 

Registrant's telephone number, including area code: (917) 595-2850

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of exchange on which registered
Common Stock, Par Value $0.0001 Per Share   PMCB  

The Nasdaq Stock Market LLC

         

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this Chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

   

 

 

Item 3.03 Material Modification to Rights of Security Holders.

 

To the extent required by Item 3.03 of Form 8-K, the information contained in Item 5.03 of this Current Report on Form 8-K is incorporated herein by reference.

 

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

 

On November 10, 2026, PharmaCyte Biotech, Inc., a Nevada corporation (the “Company”), filed with the Secretary of State of the State of Nevada a certificate of amendment (the “Certificate of Amendment”) to its Articles of Incorporation, as amended, to effect a reverse stock split of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), at a ratio of 1-for-19 (the “Reverse Stock Split”), with an effective date of November 12, 2026. The Reverse Stock Split was approved by the Company’s stockholders at the Company’s annual meeting of stockholders held on March 30, 2026, which authorized the Company’s board of directors to effect a reverse stock split at a ratio between 1-for-1.1 and 1-for-100. Pursuant to the Certificate of Amendment, the Reverse Stock Split became effective as of 4:01 p.m. Eastern Time on November 12, 2026 (the “Effective Time”), and the Common Stock began trading on a split-adjusted basis at the open of trading on The Nasdaq Capital Market on November 13, 2026. At the Effective Time, every nineteen (19) shares of the Company’s issued and outstanding Common Stock were automatically combined and converted into one (1) share of Common Stock, without any change in the par value per share. In addition, proportionate adjustments were made to the per share exercise price and the number of shares issuable upon the exercise of all outstanding stock options, warrants and convertible securities, and to the number of shares issued and issuable under the Company’s equity incentive plans. No change was made to the number of shares of Common Stock authorized under the Company’s Articles of Incorporation, as amended. Any stockholder who would otherwise be entitled to a fractional share of Common Stock created as a result of the Reverse Stock Split is entitled to receive a cash payment in lieu thereof equal to the fractional share to which the stockholder would otherwise be entitled multiplied by the closing sales price of a share of Common Stock on The Nasdaq Capital Market on the trading day immediately prior to the Effective Time, as adjusted for the Reverse Stock Split.

 

Following the Reverse Stock Split, the shares of Common Stock continue to trade on The Nasdaq Capital Market under the symbol “PMCB.” The new CUSIP number for the Common Stock following the Reverse Stock Split is 71715X302.

 

The foregoing description of the Certificate of Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Certificate of Amendment, a copy of which is attached as Exhibit 3.1 to this Current Report on Form 8-K and incorporated herein by reference.

 

Item 8.01 Other Events.

 

On November 11, 2026, the Company issued a press release announcing the Reverse Stock Split. The press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.   Description
3.1   Certificate of Amendment to the Articles of Incorporation, as amended, of PharmaCyte Biotech, Inc.
99.1   Press Release issued by PharmaCyte Biotech, Inc., dated November 11, 2026.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

 2 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

     
  PHARMACYTE BIOTECH, INC.
   
Date: November 13, 2026  
     
  By: /s/ Joshua N. Silverman
  Name: Joshua N. Silverman
  Title: Chief Executive Officer and President

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 3 

Exhibit 99.1

 

PharmaCyte Biotech, Inc. Announces Reverse Stock Split

 

PharmaCyte’s common stock is expected to begin trading on a post-split adjusted basis on November 13, 2026

 

LAS VEGAS--(BUSINESS WIRE)—November 11, 2026—PharmaCyte Biotech, Inc. (Nasdaq:PMCB) (“PharmaCyte” or the “Company”), today announced that the board of directors of the Company approved a 1-for-19 reverse stock split (the “Reverse Split”) of the Company’s common stock. The Reverse Split was approved by the stockholders at the Company’s annual meeting of the stockholders held on March 30, 2026. The Reverse Split will legally take effect at 4:01 p.m. Eastern Time, on November 12, 2026. The Company’s common stock will open for trading under a new CUSIP number 71715X 302 on The Nasdaq Capital Market on November 13, 2026, on a split-adjusted basis under the current ticker symbol “PMCB.” The Reverse Split is intended to increase the per share trading price of the Company’s common stock to enable the Company to regain compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market.

 

The 1-for-19 Reverse Split will automatically convert every nineteen (19) current shares of the Company’s common stock into one (1) share of common stock. No fractional shares will be issued in connection with the Reverse Split. Stockholders who would otherwise hold a fractional share of the Company’s common stock following the Reverse Split will receive a cash payment in lieu thereof equal to the fractional share to which the stockholder would otherwise be entitled multiplied by the closing sales price of a share of the Company’s common stock on The Nasdaq Capital Market, on November 12, 2026 (the last trading day prior to the commencement of split-adjusted trading), as adjusted for the Reverse Split

 

The Reverse Split will reduce the number of shares of outstanding common stock from approximately 10,755,649 shares, the number of shares outstanding as of November 11, 2026, to approximately 566,087 shares. The total authorized number of shares will not be reduced. Proportional adjustments will also be made to the exercise and conversion prices of the Company’s outstanding stock options, warrants and convertible securities, and to the number of shares issued and issuable under the Company’s stock incentive plans.

 

Stockholders holding their shares electronically in book-entry form are not required to take any action to receive post-split shares. Stockholders owning shares through a bank, broker, or other nominee will have their positions automatically adjusted to reflect the Reverse Split, subject to brokers’ particular processes, and will not be required to take any action in connection with the Reverse Split. For those stockholders holding physical stock certificates, the Company’s transfer agent, Equiniti Trust Company, LLC, will send instructions for exchanging those certificates for shares held electronically in book-entry form or for new certificates, in either case representing the post-split number of shares, and any payments in cash in lieu of fractional shares, if applicable.

 

Forward Looking Statements

 

Any statements in this press release about our future expectations, plans and prospects, including statements regarding our strategy, future operations, prospects, plans and objectives, the timing and effectiveness of the Reverse Split, the Company’s ability to regain compliance with the Nasdaq minimum bid price and other listing requirements and other statements containing the words “believes,” “anticipates,” “plans,” “expects,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including statements regarding the Company’s current objectives. These statements are based on the Company’s current expectations and beliefs and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. Additional information regarding these and other risks and uncertainties is contained in the Company’s filings with the Securities and Exchange Commission, including the Company’s most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q.

 

Investor Contact:

CORE IR

ir@pharmacyte.com

 

Media Contact:

Jules Abraham

CORE IR

Telephone: 917.885.7378

Email: julesa@coreir.com

Filing Exhibits & Attachments

5 documents

Keep reading